🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  2. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  3. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Ophthalmics Europe

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  4. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  5. ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, Orforglipron, Placebo to match LY, ORFORGLIPRON

    Eli Lilly Co.

    Hypertension

    phase 3 small molecule active

    1 trial

  6. OT-101

    Oncotelic Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  7. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Cancer Prevention Pharma (Ireland) Limited

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  8. Obexelimab

    Zenas BioPharma

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  9. Obexelimab

    Zenas BioPharma

    IgG4 Related Disease

    phase 3 small molecule active

    1 trial

  10. Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab

    Beone Medicines Ireland Limited

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  11. Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, -

    Roche Registration Limited

    Neurological Disease

    phase 3 small molecule active

    1 trial

  12. Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo ocrelizumab, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  13. Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  14. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match LY

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  15. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match, Orforglipron, Orforglipron

    Eli Lilly Co.

    Chronic Kidney Disease, Atherosclerosis Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  16. Orforglipron, Orforglipron, Orforglipron, Placebo to match ly, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  17. Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  18. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  19. Oxycodone Naltrexone (a)

    ELITE PHARMACEUTICALS INC /NV/

    Pain

    phase 3 small molecule completed

    1 trial

  20. Oxycodone/Naltrexone Capsules

    ELITE PHARMACEUTICALS INC /NV/

    Withdrawal Symptoms

    phase 3 small molecule completed

    1 trial

  21. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Ophthalmics Europe

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  22. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Cancer Prevention Pharma (Ireland) Limited

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  23. PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN

    Eli Lilly Co.

    Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  24. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources